Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04861402
Other study ID # 31589920.7.1001.5505
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date April 30, 2020
Est. completion date December 15, 2021

Study information

Verified date April 2021
Source Federal University of São Paulo
Contact Gisele GS Silva, Sampio
Phone +5511983580583
Email giselesampaio@hotmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The use of non-invasive intracranial pressure monitoring, including intracranial pressure pulse morphology in patients with COVID-19, could calculate possible components associated with the presence of neurological symptoms in these patients, in addition to being a tool with the potential to monitor the repercussion of MV at cerebral compliance patient patients. In addition, it is likely that patients with COVID-19 also have cerebral embolization more frequently than healthy patients, which is justified by transcranial doppler ultrasound assessment. The aim of the study is to monitor this brain pressure using a non-invasive method of monitoring, with a helmet-like system in place, for 1 hour for 7 consecutive days. There will be no associated invasive procedure of any kind. Monitoring will be done by the criteria themselves, no place where the patient and the mandatory volunteer. Another objective is to capture signs of microembolisms (small strokes that have not yet manifested) by performing a doppler ultrasound on the head with a helmet also for 1 hour, in a single evaluation. The study population will include inpatients with COVID-19 infection. The control group will be in patients who do not have Covid-19. The control group will consist of people with similar characteristics and who have not recovered. Patients who meet the inclusion criteria incorporated into the monitoring with a non-invasive intracranial pressure device for 1 hour during hospitalization (Brain4Care® device approved by ANVISA), being monitored for up to seven days, in addition to monitoring for 1 hour with a transcranial doppler ultrasound helmet DWL® in a single assessment. There will be no invasive procedures or other equipment used without due knowledge by Organs competent bodies. It does not collect collection or retention of any biological material.


Description:

INTRODUCTION: The Coronavirus Disease 2019 (COVID-19) is an infectious disease transmitted one person to another mainly from cough and sneeze aerosols as well as from contaminated surfaces. The most common respiratory symptoms are dry cough, fever, and dyspnea, but the Severe Respiratory Acute Syndrome (SARS) can be installed increasing disease´s mortality. In addition, neurological symptoms have been described according the increase of severity and age. Changes of intracranial pressure (ICP) can partially explain the Central Nervous System (CNS) impairment due to COVID-19. The ICP waveform can bring relevant information about intracranial compliance, and, nowadays, it can be measured by non-invasive technology. Clinically, non-invasive ICP waveform assessment would help to understand the repercussion of Invasive Mechanical Ventilation (IMV) on CNS in COVID-19 persons. AIMS: This study aims to evaluate the ICP waveform in intubated and non-intubated COVID-19 persons. Furthermore, the association between ICP and IMV parameters, level of sedation, heart rate variability, neurological symptoms, neuroimage, and final discharge will be investigated. . METHODS: At least 30 COVID-19 individuals will be included within 72h from admission and 14 days from symptoms onset. They will be divided into two groups: non-intubated (n=15) and intubated, paired with non-COVID-19 ones (non-intubated and intubated non-COVID-19 groups, respectively). The non-invasive ICP monitoring will be daily performed for 7 consecutive days. The Brain4Care's device and Analytic System will be used to assess the three pulse peaks (P1, 2 and 3) at the ICP waveform. The following variables will be investigated: P1 and P2 amplitude, P2/P1 ratio, time to peak and time percentage of P2 higher than P1. For statistics, all variables will be tested as to their normal or non-normal distribution through appropriate statical analyzes. For basic demographic and clinical variables, descriptive data analysis will be used. The repetitive measurement Anova will be used for ICP outcomes throughout the days. Pearson's or Spearman´s correlations will be applied according to data distribution.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date December 15, 2021
Est. primary completion date July 15, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: For COVID-19 group: - Men and women (not pregnant) Older than 18 years old Diagnosis of COVID-19 confirmed by Reverse Transcription Polymerase Chain Reaction (RT-PCR) Subjects intubated or non-intubated Time between admission and study inclusion = 72h For intubated group time between IUC admission and study inclusion = 72h Time between onset symptoms and study inclusion = 14 days No neurological acute disease No cutaneous injury in the head to impossibility the ICP monitoring ICF signed by the participant or his/her legal representative* No cutaneous injury in the head to impossibility the monitoring with the transcranial doppler helmet Patients who have not been submitted to decompressive craniectomy previously. Subjects intubated or non-intubated For intubated group time between IUC admission and study inclusion = 72h Time between admission and study inclusion = 72h Time between onset symptoms and study inclusion =14 days No neurological acute disease For Controls Group: Men and women (not pregnant) Older than 18 years old No cutaneous injury in the head to impossibility the ICP monitoring • For intubated group: ICF signed by the participant or his/her legal representative* Intubated patients for others causes than COVID-19 or neurological diseases IUC admission and study inclusion = 72h No symptoms of COVID-19 on the last 15 days • For healthy group: No previous neurological disease No chronic disease as Diabetes Mellitus Type 2, Chronic Obstructive Pulmonary Disease (COPD), Heart Failure, hypertension or Chronic Kidney Disease (CKD) No cutaneous injury in the head to impossibility the monitoring with the transcranial doppler helmet Patients who have not been submitted to decompressive craniectomy previously. IUC admission and study inclusion = 72h No neurological diseases Exclusion Criteria: - It will be excluded those who asked to stop their participation, and those with problems in acquiring ICP data.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
The ICP monitoring will be performed in a non-invasive method developed by Brain4Care
The ICP monitoring will be performed in a non-invasive way through the cranial deformation method developed by Brain4Care Inc. The selected patients will be monitored until 1h/day for 7 sequential days or even discharge. The clinical outcomes such as ventilatory status will be noted (if the subject is under oxygen supplementation, using non-invasive mechanical ventilation or intubated), the ventilatory parameters during the monitorization will be analyzed in the intubated group (or those from a non-intubated group who was intubated during the seven days of hospitalization) including IFO2, CV, PEEP, driving pressure, and pressure plate as well as ventilatory asynchronies. Some changes in ventilatory parameters during monitorization will be noted. These procedures will be applied to all groups, excepted to the healthy group. This last group will be monitored only once for 30 minutes at the Federal University of São Carlos (UFSCar).

Locations

Country Name City State
Brazil Hospital São Paulo São Paulo SP

Sponsors (2)

Lead Sponsor Collaborator
Federal University of São Paulo Sens4care

Country where clinical trial is conducted

Brazil, 

References & Publications (8)

Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, Evaluation, and Treatment of Coronavirus (COVID-19). 2021 Mar 1. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from http://www.ncbi.nlm.nih.gov/b — View Citation

Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, Breitbart RE, Acton S. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ R — View Citation

Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W, Duan G. Virology, Epidemiology, Pathogenesis, and Control of COVID-19. Viruses. 2020 Mar 27;12(4). pii: E372. doi: 10.3390/v12040372. Review. — View Citation

Paniz-Mondolfi A, Bryce C, Grimes Z, Gordon RE, Reidy J, Lednicky J, Sordillo EM, Fowkes M. Central nervous system involvement by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). J Med Virol. 2020 Jul;92(7):699-702. doi: 10.1002/jmv.25915. — View Citation

Su S, Wong G, Shi W, Liu J, Lai ACK, Zhou J, Liu W, Bi Y, Gao GF. Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses. Trends Microbiol. 2016 Jun;24(6):490-502. doi: 10.1016/j.tim.2016.03.003. Epub 2016 Mar 21. Review. — View Citation

Ye M, Ren Y, Lv T. Encephalitis as a clinical manifestation of COVID-19. Brain Behav Immun. 2020 Aug;88:945-946. doi: 10.1016/j.bbi.2020.04.017. Epub 2020 Apr 10. — View Citation

Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, Chen HD, Chen J, Luo Y, Guo H, Jiang RD, Liu MQ, Chen Y, Shen XR, Wang X, Zheng XS, Zhao K, Chen QJ, Deng F, Liu LL, Yan B, Zhan FX, Wang YY, Xiao GF, Shi ZL. A pneumonia outb — View Citation

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W; China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary ICP pulse waveform To evaluate the ICP pulse waveform in patients with COVID-19 non-intubated compared to healthy subjects. 01/06/2021
Primary ICP pulse waveform 2 To evaluate the ICP pulse waveform in intubated patients with COVID-19 compared to intubated subjects with other diagnoses except COVID-19. 01/06/2021
Primary spontaneous microemboli To evaluate the spontaneous microemboli presence with TCD in those subjects who received the ICP monitoring. 01/06/2021
Secondary Secondary Outcome To correlate the ICP pulse waveform and the presence of neurological symptoms on hospital admission in the non-intubated COVID-19 group 01/06/21
Secondary Secondary Outcome 1 To correlate the ICP pulse waveform and the emergence of neurological symptoms during the admission in the non-intubated COVID-19 group 01/06/2021
Secondary Secondary Outcome 2 To correlate the ICP pulse waveform and the necessity of intubation during hospitalization time in the non-intubated COVID-19 group 01/06/2021
Secondary Secondary Outcome 3 To correlate the ICP pulse waveform and the Heart Rate Variability in the non-intubated COVID-19 group 01/06/2021
Secondary Secondary Outcome 4 To correlate the ICP pulse waveform and neuroimaging when available in the non-intubated COVID-19 group 01/06/2021
Secondary Secondary Outcome 5 To correlate the ICP pulse waveform and the outcome on discharge in the non-intubated COVID-19 group 01/06/2021
Secondary Secondary Outcome 6 To correlate the ICP pulse waveform to ventilatory parameters (inspired fraction of oxygen [IFO2], PEEP, Current Volum [CV] and driving pressure) in the intubated COVID-19 group 01/06/2021
Secondary Secondary Outcome 7 To correlate the ICP pulse waveform to sedation used in the intubated COVID-19 group 01/06/2021
Secondary Secondary Outcome 8 To correlate the ICP pulse waveform to HRV in the intubated COVID-19 group 01/06/2021
Secondary Secondary Outcome 9 To correlate the ICP pulse waveform and the neurological symptoms on hospital admission in the intubated COVID-19 group 01/06/2021
Secondary Secondary Outcome 10 To correlate the ICP pulse waveform and the outcome at hospital discharge in the intubated COVID-19 group 01/06/2021
Secondary Secondary Outcome 11 To correlate the ICP pulse waveform and to neuroimaging when available in the intubated COVID-19 group 01/06/2021
See also
  Status Clinical Trial Phase
Withdrawn NCT04288076 - The Brain and Lung Interaction (BALI) Study N/A
Recruiting NCT01745081 - Comparison of 20% Mannitol and 3% Hypertonic Saline for Cerebral Relaxation During Elective Supratentorial Craniotomies Phase 4
Recruiting NCT06027567 - The Effect of an Anti-obesity Drug, Semaglutide, as Treatment in New-onset Idiopathic Intracranial Hypertension (IIH) Compared to Standard Weight Management (Dietician) With Regards to Change in Weight and Intracranial Pressure Phase 4
Active, not recruiting NCT05068128 - Combined Flow and Pressure Study of Craniospinal Dynamic
Recruiting NCT03087981 - Parameters Analysis in Neurosurgical Critical Patients Through Big Data Acquisition N/A
Withdrawn NCT03933254 - Intraocular Pressure and Optic Nerve Sheath Diameter Changes in Laparoscopic Cholecystectomies
Completed NCT04849221 - Wideband Tympanometry for Monitoring Intracranial Pressure in Adult Patients in Intensive Care, Operated on for an Intracranial Lesion After Traumatic Brain Injury, or With Intracranial Hemorrhage
Recruiting NCT03144297 - Intracranial Pressure vs Percentage Body Fat N/A
Not yet recruiting NCT03853889 - Evaluation of the Effect on Optic Nerve Sheath Diameter in Patients Undergoing Cesarean Section N/A
Not yet recruiting NCT06368648 - CoMind Early Feasibility Study
Recruiting NCT04910087 - The Effect of Anesthesia Management on Optic Nerve Sheath Diameter in the Ercp Procedures N/A
Recruiting NCT03382860 - Estimation of Intracranial Pressure Using Non-invasive Fundus Videos
Completed NCT01330264 - Study of Intracranial Pressure (ICP) Monitoring in Critically Ill N/A
Terminated NCT03938402 - Intraocular Pressure and Optic Nerve Sheath Diameter Changes at Different PEEP Levels N/A
Completed NCT05501613 - Early Multimodal Neuromonitoring For Spontaneous Intracerebral Hemorrhage (ICH)
Completed NCT01685476 - NIMI-NICU: Non Invasive Monitoring of the Intracranial Pressure - NeuroIntensive Care Unit Phase 4
Completed NCT00538616 - Precedex Versus Propofol-Awakening for Reducing Brain Injury Expansion Phase 1/Phase 2
Completed NCT00597831 - Regulation of Intracerebral Pressure During Electroconvulsive Therapy N/A
Terminated NCT00279097 - Safety Study to Evaluate Intracranial Pressure During High Frequency Chest Wall Oscillation N/A
Completed NCT03097523 - Mitigating Cephalad Fluid Shifts: A NSBRI Study N/A